1. Home
  2. BOE vs ARVN Comparison

BOE vs ARVN Comparison

Compare BOE & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock Enhanced Global Dividend Trust of Beneficial Interest

BOE

Blackrock Enhanced Global Dividend Trust of Beneficial Interest

N/A

Current Price

$11.35

Market Cap

649.4M

Sector

Finance

ML Signal

N/A

Logo Arvinas Inc.

ARVN

Arvinas Inc.

N/A

Current Price

$7.53

Market Cap

600.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BOE
ARVN
Founded
2005
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
649.4M
600.2M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
BOE
ARVN
Price
$11.35
$7.53
Analyst Decision
Buy
Analyst Count
0
15
Target Price
N/A
★ $14.54
AVG Volume (30 Days)
166.4K
★ 679.4K
Earning Date
01-01-0001
11-03-2026
Dividend Yield
★ 7.30%
N/A
EPS Growth
N/A
★ 58.84
EPS
N/A
★ 1.70
Revenue
N/A
★ $262,600,000.00
Revenue This Year
N/A
$12.96
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$4.65
Revenue Growth
★ N/A
N/A
52 Week Low
$10.59
$6.74
52 Week High
$12.58
$14.22

Technical Indicators

Market Signals
Indicator
BOE
ARVN
Relative Strength Index (RSI) 39.11 48.35
Support Level $11.14 $6.74
Resistance Level $11.99 $7.77
Average True Range (ATR) 0.17 0.36
MACD 0.01 0.09
Stochastic Oscillator 30.65 62.79

Price Performance

Historical Comparison
BOE
ARVN

About BOE Blackrock Enhanced Global Dividend Trust of Beneficial Interest

Blackrock Enhanced Global Dividend Trust is a closed-end management investment company. Its investment objective is to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing in equity securities issued by companies located in countries throughout the world.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: